-
1
-
-
0035095675
-
New insights into the second generation antihistamines
-
Walsh GM, Annunziato L, Frossard N, Knol K, Levander S, Nicolas JM, et al. New insights into the second generation antihistamines. Drugs 2001;61:207-36.
-
(2001)
Drugs
, vol.61
, pp. 207-236
-
-
Walsh, G.M.1
Annunziato, L.2
Frossard, N.3
Knol, K.4
Levander, S.5
Nicolas, J.M.6
-
2
-
-
0032919046
-
Second-generation antihistamines: A comparative review
-
Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999;57:31-47.
-
(1999)
Drugs
, vol.57
, pp. 31-47
-
-
Slater, J.W.1
Zechnich, A.D.2
Haxby, D.G.3
-
5
-
-
0034105501
-
Evaluation of the cardiac safety of second-generation antihistamines
-
Taglialatela M, Annunziato L. Evaluation of the cardiac safety of second-generation antihistamines. Allergy 2000;55:22-30.
-
(2000)
Allergy
, vol.55
, pp. 22-30
-
-
Taglialatela, M.1
Annunziato, L.2
-
6
-
-
0032896891
-
Second-generation antihistamines: The risk of ventricular arrhythmias
-
DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999;21:281-95.
-
(1999)
Clin Ther
, vol.21
, pp. 281-295
-
-
DuBuske, L.M.1
-
7
-
-
0026427907
-
Allergic rhinitis
-
Naclerio RM. Allergic rhinitis. N Engl J Med 1991;325:860-9.
-
(1991)
N Engl J Med
, vol.325
, pp. 860-869
-
-
Naclerio, R.M.1
-
8
-
-
0034912161
-
Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis
-
Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108(suppl):S2-8.
-
(2001)
J Allergy Clin Immunol
, vol.108
, Issue.SUPPL.
-
-
Skoner, D.P.1
-
9
-
-
0034500798
-
Allergic rhinitis: Not purely a histamine-related disease
-
Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55(suppl)64:7-16.
-
(2000)
Allergy
, vol.55
, Issue.64 SUPPL.
, pp. 7-16
-
-
Howarth, P.H.1
Salagean, M.2
Dokic, D.3
-
10
-
-
0035137186
-
The pharmacologic profile of desloratadine: A review
-
Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001;56(suppl 65):7-13.
-
(2001)
Allergy
, vol.56
, Issue.SUPPL. 65
, pp. 7-13
-
-
Henz, B.M.1
-
13
-
-
0033999939
-
1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
-
1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-52.
-
(2000)
Arzneimittelforschung
, vol.50
, pp. 345-352
-
-
Kreutner, W.1
Hey, J.A.2
Anthes, J.3
Barnett, A.4
Young, S.5
Tozzi, S.6
-
16
-
-
0030968998
-
Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
-
Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997:27:559-67.
-
(1997)
Clin Exp Allergy
, vol.27
, pp. 559-567
-
-
Genovese, A.1
Patella, V.2
De Crescenzo, G.3
De Paulis, A.4
Spadaro, G.5
Marone, G.6
-
19
-
-
0034845227
-
Inhibition of cytokine generation and mediator release in human basophils with desloratadine
-
Schroeder T, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release in human basophils with desloratadine. Clin Exp Allergy 2001;31:1369-77.
-
(2001)
Clin Exp Allergy
, vol.31
, pp. 1369-1377
-
-
Schroeder, T.1
Schleimer, R.P.2
Lichtenstein, L.M.3
Kreutner, W.4
-
20
-
-
0029010698
-
Inhibitory activity of loratadine and descarboxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells
-
Vignola AM, Crampette L, Mondain M, Sauvere G, Czarlewski W, Bousquet J, et al. Inhibitory activity of loratadine and descarboxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50:200-3.
-
(1995)
Allergy
, vol.50
, pp. 200-203
-
-
Vignola, A.M.1
Crampette, L.2
Mondain, M.3
Sauvere, G.4
Czarlewski, W.5
Bousquet, J.6
-
21
-
-
0034908639
-
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule I upregulation and promoter activation in respiratory epithelial cells
-
Papi A, Papadopoulos NG, Stanciu LA, Degitz K, Holgate ST, Johnston SL. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule I upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001;108:221-8.
-
(2001)
J Allergy Clin Immunol
, vol.108
, pp. 221-228
-
-
Papi, A.1
Papadopoulos, N.G.2
Stanciu, L.A.3
Degitz, K.4
Holgate, S.T.5
Johnston, S.L.6
-
22
-
-
0030800848
-
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-I expression
-
Ciprandi G, Pronzato C, Passalaqua G, Danzig M, Canonica GW. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-I expression. Clin Exp Allergy 1997;27:1175-83.
-
(1997)
Clin Exp Allergy
, vol.27
, pp. 1175-1183
-
-
Ciprandi, G.1
Pronzato, C.2
Passalaqua, G.3
Danzig, M.4
Canonica, G.W.5
-
23
-
-
0023741518
-
Inhibition of eosinophil chemotaxis by new antiallergic compound (cetirizine)
-
Leprevost C, Capron M, De Vos C, Tomassini M, Capron AL. Inhibition of eosinophil chemotaxis by new antiallergic compound (cetirizine). Int Arch Allergy Appl Immunol 1988;87:9-13.
-
(1988)
Int Arch Allergy Appl Immunol
, vol.87
, pp. 9-13
-
-
Leprevost, C.1
Capron, M.2
De Vos, C.3
Tomassini, M.4
Capron, A.L.5
-
24
-
-
0031920720
-
Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis
-
Abdelaziz H, Davakua JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20.
-
(1998)
J Allergy Clin Immunol
, vol.101
, pp. 410-420
-
-
Abdelaziz, H.1
Davakua, J.L.2
Khair, O.A.3
Bayram, H.4
Prior, A.J.5
Davies, R.J.6
-
25
-
-
0026049747
-
Suppressive effect of loratadine on allergen-induced histamine release in the nose
-
Andersson M, Nolte H, Baumgarten C, Pipkorn U. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991;46:540-6.
-
(1991)
Allergy
, vol.46
, pp. 540-546
-
-
Andersson, M.1
Nolte, H.2
Baumgarten, C.3
Pipkorn, U.4
-
27
-
-
0029775852
-
Overview of allergic mechanisms. Ebastine has more than an antihistamine effect
-
Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996;52(suppl 1):15-9.
-
(1996)
Drugs
, vol.52
, Issue.SUPPL. 1
, pp. 15-19
-
-
Campbell, A.1
Michel, F.B.2
Bremard-Oury, C.3
Crampette, L.4
Bousquet, J.5
-
29
-
-
0033032096
-
Histamine and tryptase in nasal lavage fluid after allergen challenge: Effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine
-
Jacobi HH, Skov PS, Poulsen LK, Malling HJ, Mygind N. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999;103(5, pt 1):768-72.
-
(1999)
J Allergy Clin Immunol
, vol.103
, Issue.5 PART 1
, pp. 768-772
-
-
Jacobi, H.H.1
Skov, P.S.2
Poulsen, L.K.3
Malling, H.J.4
Mygind, N.5
-
30
-
-
9244253690
-
Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis
-
Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-21.
-
(1996)
J Allergy Clin Immunol
, vol.97
, pp. 915-921
-
-
Bronsky, E.A.1
Dockhorn, R.J.2
Meltzer, E.O.3
Shapiro, G.4
Boltansky, H.5
LaForce, C.6
-
31
-
-
0025009223
-
Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clearcut relationship to eosinophil influx
-
Klementsson H, Andersson M, Pipkorn U. Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clearcut relationship to eosinophil influx. J Allergy Clin Immunol 1990;86(4, pt 1):466-72.
-
(1990)
J Allergy Clin Immunol
, vol.86
, Issue.4 PART 1
, pp. 466-472
-
-
Klementsson, H.1
Andersson, M.2
Pipkorn, U.3
-
32
-
-
0029055475
-
Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics
-
Roquet A, Raud J, Hallden G, van Hage-Hamsten M, Hed J, Hansson LO, et al. Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy 1995;50:414-20.
-
(1995)
Allergy
, vol.50
, pp. 414-420
-
-
Roquet, A.1
Raud, J.2
Hallden, G.3
Van Hage-Hamsten, M.4
Hed, J.5
Hansson, L.O.6
-
33
-
-
0029116991
-
Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy
-
Ciprandi G. Pronzato C, Ricca V, Varese P, Del Giacco GS, Canonica GW. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy 1995;25:871-8.
-
(1995)
Clin Exp Allergy
, vol.25
, pp. 871-878
-
-
Ciprandi, G.1
Pronzato, C.2
Ricca, V.3
Varese, P.4
Del Giacco, G.S.5
Canonica, G.W.6
-
34
-
-
0028897165
-
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and latephase reactions after allergen-specific challenge
-
Ciprandi G, Buscaglia S, Pesce G, Passalacqua G. Rihoux JP, Bagnasco M, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and latephase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612-21.
-
(1995)
J Allergy Clin Immunol
, vol.95
, pp. 612-621
-
-
Ciprandi, G.1
Buscaglia, S.2
Pesce, G.3
Passalacqua, G.4
Rihoux, J.P.5
Bagnasco, M.6
-
35
-
-
85004775232
-
Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo
-
Fadel R, Herpin-Richard N, Rihoux JP, Henocq E. Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy 1987;17:373-9.
-
(1987)
Clin Allergy
, vol.17
, pp. 373-379
-
-
Fadel, R.1
Herpin-Richard, N.2
Rihoux, J.P.3
Henocq, E.4
-
36
-
-
0029780284
-
A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness
-
Bentley AM, Walker S, Hanotte F, De Vos C, Durham SR. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy 1996;26:909-17.
-
(1996)
Clin Exp Allergy
, vol.26
, pp. 909-917
-
-
Bentley, A.M.1
Walker, S.2
Hanotte, F.3
De Vos, C.4
Durham, S.R.5
-
38
-
-
0034808214
-
Intranasal corticosteroids for allergic rhinitis: Superior relief?
-
Nielsen LP, Mygina N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs 2001;61:1563-79.
-
(2001)
Drugs
, vol.61
, pp. 1563-1579
-
-
Nielsen, L.P.1
Mygina, N.2
Dahl, R.3
-
39
-
-
0034023585
-
The clinical relevance of the anti-inflammatory properties of antihistamines
-
Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2001;55:53-61.
-
(2001)
Allergy
, vol.55
, pp. 53-61
-
-
Walsh, G.M.1
-
40
-
-
0036117934
-
Rethinking our approach to allergic rhinitis management
-
Storms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002;88(suppl):30-5.
-
(2002)
Ann Allergy Asthma Immunol
, vol.88
, Issue.SUPPL.
, pp. 30-35
-
-
Storms, W.W.1
-
41
-
-
0031946273
-
A review of the current guidelines for allergic rhinifis and asthma
-
Lemanske RF. A review of the current guidelines for allergic rhinifis and asthma. J Allergy Clin Immunol 1998;101(2, pt 2):S392-6.
-
(1998)
J Allergy Clin Immunol
, vol.101
, Issue.2 PART 2
-
-
Lemanske, R.F.1
-
43
-
-
0001352356
-
The effect of food on the oral bioavailability of desloratadine
-
Gupta S, Padhi D, Banfield C, Marbury T, Affrime MB. The effect of food on the oral bioavailability of desloratadine (abstract). J Allergy Clin Immunol 2000;105(1, pt 2):S387.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Gupta, S.1
Padhi, D.2
Banfield, C.3
Marbury, T.4
Affrime, M.B.5
-
44
-
-
0000625730
-
Doseproportionality, linearity, and pharmacokinetics of desloratadine in healthy adults
-
Herron JM, Padhi D, Affrime MB, Glue P, Gupta S, Banfield C. Doseproportionality, linearity, and pharmacokinetics of desloratadine in healthy adults (abstract). J Allergy Clin Immunol 2000;105(1, pt2):S385.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Herron, J.M.1
Padhi, D.2
Affrime, M.B.3
Glue, P.4
Gupta, S.5
Banfield, C.6
-
45
-
-
0000900182
-
Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers
-
Padhi D, Banfield C, Gupta S, Glue P, Affrime MB. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers (abstract). J Allergy Clin Immunol 2000;105(1, pt 2):S385.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Padhi, D.1
Banfield, C.2
Gupta, S.3
Glue, P.4
Affrime, M.B.5
-
46
-
-
4244023430
-
Pharmacokinetic equivalence of pediatric dosages of desloratadine syrup in children and standard 5 mg desloratadine tablets in adults
-
Banfield C, Gupta S, Affrime M, Batra V. Pharmacokinetic equivalence of pediatric dosages of desloratadine syrup in children and standard 5 mg desloratadine tablets in adults (abstract). J Allergy Clin Immunol 2002;109(2, pt 2):S103.
-
(2002)
J Allergy Clin Immunol
, vol.109
, Issue.PART 2
-
-
Banfield, C.1
Gupta, S.2
Affrime, M.3
Batra, V.4
-
47
-
-
0034876431
-
In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OHdesloratadine for five human cytochrome P450 enzymes
-
Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OHdesloratadine for five human cytochrome P450 enzymes. Drug Metab Dispos 2001;29:1173-5.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 1173-1175
-
-
Barecki, M.E.1
Casciano, C.N.2
Johnson, W.W.3
Clement, R.P.4
-
48
-
-
85036691936
-
-
Kenilworth, NJ: Schering Corp., September
-
Package insert. Claritin (loratadine). Kenilworth, NJ: Schering Corp., September 2000.
-
(2000)
Package Insert. Claritin (Loratadine)
-
-
-
49
-
-
0001352357
-
Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender
-
Rosenberg MA, Cohen A, Padhi D, Banfield C, Gupta S, Affrime MB. Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender (abstract). J Allergy Clin Immunol 2000;105(1, pt 2): S386.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Rosenberg, M.A.1
Cohen, A.2
Padhi, D.3
Banfield, C.4
Gupta, S.5
Affrime, M.B.6
-
50
-
-
0035126404
-
1-receptor antagonist, in patients with seasonal allergic rhinitis; assessment during the Spring and Fall allergy seasons
-
1-receptor antagonist, in patients with seasonal allergic rhinitis; assessment during the Spring and Fall allergy seasons. Clin Drug Invest 2001;21:25-32.
-
(2001)
Clin Drug Invest
, vol.21
, pp. 25-32
-
-
Meltzer, E.O.1
Prenner, B.M.2
Nayak, A.3
-
51
-
-
0001075185
-
Efficacy and safety of desloratadine in seasonal allergic rhinitis
-
Salmun LM, Lober R, Danzig M, Staudinger H. Efficacy and safety of desloratadine in seasonal allergic rhinitis (abstract). J Allergy Clin Immunol 2000;105(1, pt 2):S384.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Salmun, L.M.1
Lober, R.2
Danzig, M.3
Staudinger, H.4
-
52
-
-
0036279872
-
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit
-
Horak F, Stubner UP, Zieglmayer I, Ing D, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956-61.
-
(2002)
J Allergy Clin Immunol
, vol.109
, pp. 956-961
-
-
Horak, F.1
Stubner, U.P.2
Zieglmayer, I.3
Ing, D.4
Harris, A.G.5
-
53
-
-
0035131070
-
Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis
-
Bechert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56:14-20.
-
(2001)
Allergy
, vol.56
, pp. 14-20
-
-
Bechert, C.1
-
54
-
-
0001075184
-
Decongestant effects of desloratadine in patients with seasonal allergic rhinitis
-
Nayak A, Lorbert R, Salman LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis (abstract). J Allergy Clin Immunol 2000;105(1, pt 2):S384.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Nayak, A.1
Lorbert, R.2
Salman, L.M.3
-
55
-
-
0034748476
-
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis
-
Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. J Allergy Clin Immunol 2001;56:1077-80.
-
(2001)
J Allergy Clin Immunol
, vol.56
, pp. 1077-1080
-
-
Nayak, A.S.1
Schenkel, E.2
-
56
-
-
0001087070
-
Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma
-
Shapiro GG, the Desloratadine Study Group. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol 2001;107:S161.
-
(2001)
J Allergy Clin Immunol
, vol.107
-
-
Shapiro, G.G.1
-
57
-
-
0013062205
-
Fixed-dose desloratadine and pseudoepedrine relieves moderate/severe nasal congestion in patients with seasonal allergic rhinifis
-
Schenkel E, Corren J, Murray JJ. Fixed-dose desloratadine and pseudoepedrine relieves moderate/severe nasal congestion in patients with seasonal allergic rhinifis (abstract). J Allergy Clin Immunol 2002;109(2, pt 2):S103.
-
(2002)
J Allergy Clin Immunol
, vol.109
, Issue.2 PART 2
-
-
Schenkel, E.1
Corren, J.2
Murray, J.J.3
-
58
-
-
0001087071
-
Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma
-
Berger WE, the Desloratadine Study Group. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol 2001;107(2, pt 2):S162.
-
(2001)
J Allergy Clin Immunol
, vol.107
, Issue.2 PART 2
-
-
Berger, W.E.1
-
59
-
-
0001087069
-
Desloratadine reduces the use of inhaled beta 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma
-
Corren J, the Desloratadine Study Group. Desloratadine reduces the use of inhaled beta 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol 2001;107(2, pt 2):S163.
-
(2001)
J Allergy Clin Immunol
, vol.107
, Issue.2 PART 2
-
-
Corren, J.1
-
60
-
-
85009032463
-
Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR
-
Ratner PH. the Desloratadine Study Group. Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR (abstract). Ann Allergy Asthma Immunol 2001;86:109:P63.
-
(2001)
Ann Allergy Asthma Immunol
, vol.86
, Issue.109
-
-
Ratner, P.H.1
-
61
-
-
0000336611
-
Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks
-
Dubuske LM, the Desloratadine Study Group. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks (abstract). J Allergy Clin Immunol 2001;107(2, pt 2):S159.
-
(2001)
J Allergy Clin Immunol
, vol.107
, Issue.2 PART 2
-
-
Dubuske, L.M.1
-
62
-
-
80051499508
-
-
Kenilworth, NJ: Schering Corporation
-
Data on file. Kenilworth, NJ: Schering Corporation.
-
Data on File
-
-
-
64
-
-
0035092744
-
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
-
Ring J, Rudiger H, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:1-5.
-
(2001)
Int J Dermatol
, vol.40
, pp. 1-5
-
-
Ring, J.1
Rudiger, H.2
Gauger, A.3
Bronsky, E.4
Miller, B.5
-
65
-
-
0001339719
-
Electrocardiographic effects of multiple high doses of desloratadine
-
Banfield C, Padhi D, Glue P, Herron JM, Statkevich P, Affrime MB. Electrocardiographic effects of multiple high doses of desloratadine (abstract). J Allergy Clin Immunol 2001;104(1, pt 2):S383.
-
(2001)
J Allergy Clin Immunol
, vol.104
, Issue.1 PART 2
-
-
Banfield, C.1
Padhi, D.2
Glue, P.3
Herron, J.M.4
Statkevich, P.5
Affrime, M.B.6
-
66
-
-
0034111253
-
1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
-
1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441-8.
-
(2000)
Arzneimittelforschung
, vol.50
, pp. 441-448
-
-
Kreutner, W.1
Hey, J.A.2
Chiu, P.3
Barnett, A.4
-
68
-
-
0001041493
-
Desloratadine has no effect on wakefulness or psychomotor performance
-
Scharf MB, Kay G, Rikken G. Desloratadine has no effect on wakefulness or psychomotor performance (abstract). Allergy 2000;55(suppl 63):280.
-
(2000)
Allergy
, vol.55
, Issue.SUPPL. 63
, pp. 280
-
-
Scharf, M.B.1
Kay, G.2
Rikken, G.3
-
69
-
-
0001061710
-
Desloratadine and alcohol coadministration: No increase in impairment of performance over that induced by alcohol alone
-
Rikken G, Scharf MB, Danzig MR. Desloratadine and alcohol coadministration: no increase in impairment of performance over that induced by alcohol alone (abstract). Allergy 2000;55(suppl 63):277.
-
(2000)
Allergy
, vol.55
, Issue.SUPPL. 63
, pp. 277
-
-
Rikken, G.1
Scharf, M.B.2
Danzig, M.R.3
-
70
-
-
0027118223
-
From the US Food and Drug Administration. Warnings issued on nonsedating antihistamines terfenadine and astemizole
-
Nightingale SL. From the US Food and Drug Administration. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992;268:705.
-
(1992)
JAMA
, vol.268
, pp. 705
-
-
Nightingale, S.L.1
-
71
-
-
0001352354
-
Desloratadine and erythromycin: Pharmacokinetics and electrocardiographic pharmacodynamic effects
-
Glue P, Banfield C, Affrime MB. Desloratadine and erythromycin: pharmacokinetics and electrocardiographic pharmacodynamic effects (abstract). J Allergy Clin Immunol 2000;105(1, pt 2):S387.
-
(2000)
J Allergy Clin Immunol
, vol.105
, Issue.1 PART 2
-
-
Glue, P.1
Banfield, C.2
Affrime, M.B.3
-
72
-
-
0036071091
-
Lack of clinically relevant interaction between desloratadine and erythromycin
-
Banfield C, Hunt T, Reyderman L, Statkevicch P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002;41(suppl 1):20-35.
-
(2002)
Clin Pharmacokinet
, vol.41
, Issue.SUPPL. 1
, pp. 20-35
-
-
Banfield, C.1
Hunt, T.2
Reyderman, L.3
Statkevicch, P.4
Padhi, D.5
Affrime, M.6
-
73
-
-
0036074083
-
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole
-
Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002;41(suppl 1):37-44.
-
(2002)
Clin Pharmacokinet
, vol.41
, Issue.SUPPL. 1
, pp. 37-44
-
-
Banfield, C.1
Herron, J.2
Keung, A.3
Padhi, D.4
Affrime, M.5
-
74
-
-
0003136113
-
No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine
-
Banfield C, Gupta S, Kantesaria B. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine (abstract). J Allergy Clin Immunol 2001;107(2, pt 2):S529.
-
(2001)
J Allergy Clin Immunol
, vol.107
, Issue.2 PART 2
-
-
Banfield, C.1
Gupta, S.2
Kantesaria, B.3
-
75
-
-
0000259447
-
Effects of various cytochrome P450 inhibitors on the clearance of loratadine (L)/descarboethoxyloratadine (DCL) and lack of effects of increased L and DCL plasma concentrations on QTc intervals
-
Brannan M, Affrime M, Cayen M. Effects of various cytochrome P450 inhibitors on the clearance of loratadine (L)/descarboethoxyloratadine (DCL) and lack of effects of increased L and DCL plasma concentrations on QTc intervals (abstract). Allergy 1997;37(suppl 52):207.
-
(1997)
Allergy
, vol.37
, Issue.SUPPL. 52
, pp. 207
-
-
Brannan, M.1
Affrime, M.2
Cayen, M.3
-
76
-
-
0003218047
-
Unlike fexofenadine, the pharmacokinetics of desloratadine are minimally altered by coadministration with azithromycin
-
Gupta S, Banfield C, Lim J, Marino M, Clement RP, Affrime MB, et al. Unlike fexofenadine, the pharmacokinetics of desloratadine are minimally altered by coadministration with azithromycin (abstract). J Allergy Clin Immunol 2001;107(2, pt2):S159.
-
(2001)
J Allergy Clin Immunol
, vol.107
, Issue.2 PART 2
-
-
Gupta, S.1
Banfield, C.2
Lim, J.3
Marino, M.4
Clement, R.P.5
Affrime, M.B.6
-
77
-
-
0032904977
-
Grapefruit juice activates P-glycoprotein-mediated drug transport
-
Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharmaceutical Research 1999;16:478-85.
-
(1999)
Pharmaceutical Research
, vol.16
, pp. 478-485
-
-
Soldner, A.1
Christians, U.2
Susanto, M.3
Wacher, V.J.4
Silverman, J.A.5
Benet, L.Z.6
-
78
-
-
0000924607
-
Effect of desloratadine on P-glycoprotein transport system (MDR1)
-
Cayen M, Wang E, Clement RP. Effect of desloratadine on P-glycoprotein transport system (MDR1) (abstract). Allergy 2000;(suppl 63):S282.
-
(2000)
Allergy
, Issue.SUPPL. 63
-
-
Cayen, M.1
Wang, E.2
Clement, R.P.3
-
79
-
-
0036091282
-
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine
-
Banfield C, Samir G, Marino M. Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41:311-8.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 311-318
-
-
Banfield, C.1
Samir, G.2
Marino, M.3
Lim, J.4
Affrime, M.5
-
80
-
-
0036073476
-
Oral bioavailability of desloratadine is unaffected by food
-
Gupta S, Banfield C, Affrime M, Marbury, Padhi D, Glue P. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002;(suppl 1):7-12.
-
(2002)
Clin Pharmacokinet
, Issue.SUPPL. 1
, pp. 7-12
-
-
Gupta, S.1
Banfield, C.2
Affrime, M.3
Marbury4
Padhi, D.5
Glue, P.6
-
82
-
-
12244296941
-
Allergic rhinitis
-
Di Piro JT, Talbert RL, Yee GC, Matzke GR, Well BG, Posey LM, eds. Stanford, Connecticut:Appleton & Lange
-
May JR. Allergic Rhinitis. In: Di Piro JT, Talbert RL, Yee GC, Matzke GR, Well BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, Fourth Edition. Stanford, Connecticut:Appleton & Lange, 1999:1479-88.
-
(1999)
Pharmacotherapy: A Pathophysiologic Approach, Fourth Edition
, pp. 1479-1488
-
-
May, J.R.1
-
83
-
-
0036120561
-
The burden of allergic rhinitis: Beyond dollars and cents
-
Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88(suppl):2-7.
-
(2002)
Ann Allergy Asthma Immunol
, vol.88
, Issue.SUPPL.
, pp. 2-7
-
-
Fineman, S.M.1
-
84
-
-
0034912161
-
Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis
-
Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108(suppl):S2-8.
-
(2001)
J Allergy Clin Immunol
, vol.108
, Issue.SUPPL.
-
-
Skoner, D.P.1
-
85
-
-
12244268453
-
Antihistamine OTC switch moves to legal arena after committee votes
-
Antihistamine OTC switch moves to legal arena after committee votes. FDC Reports, The Pink Sheet 2001;63(20):34.
-
(2001)
FDC Reports, The Pink Sheet
, vol.63
, Issue.20
, pp. 34
-
-
-
86
-
-
0034884337
-
Management of allergic rhinitis and sinusitis
-
Blake K, Larsen J. Management of allergic rhinitis and sinusitis. J Pharm Prac 2001;14:228-25.
-
(2001)
J Pharm Prac
, vol.14
, pp. 228-325
-
-
Blake, K.1
Larsen, J.2
-
87
-
-
12244275479
-
Schering-Plough Clarinex launch strategy follows Nexium model
-
Schering-Plough Clarinex launch strategy follows Nexium model. FDC Reports, The Pink Sheet 2002;64(1):9-10.
-
(2002)
FDC Reports, The Pink Sheet
, vol.64
, Issue.1
, pp. 9-10
-
-
|